Sectors

RVTY
Revvity, Inc.
102.32
1 x 102.11
1 x 102.48
bid
ask
+
1.25
1.24%
12:14 PM
timesize
Ytd 5.76%
1y 10.74%
101.65
day range
104.02
82.26
52 week range
117.75
Open 102.03 Prev Close 101.07 Low 101.65 High 104.02 Mkt Cap 11.41B
Vol 343.60K Avg Vol 1.29M EPS 2.08 P/E 49.19 Forward P/E 17.24
Beta 1.05 Short Ratio 6.65 Inst. Own 105.76% Dividend 0.28 Div Yield 0.28
Ex Div Date 07-17 Earning 07-27 50-d Avg 92.58 200-d Avg 94.97 1yr Est 113.64
Earning
Date For Estimate Reported Surprise surprise %
2026-05-05 2026-03 1.02 1.06 0.04 3.92%
2026-02-02 2025-12 1.63 1.7 0.07 4.29%
2025-10-27 2025-09 1.14 1.18 0.04 3.51%
2025-07-28 2025-06 1.14 1.18 0.04 3.51%
2025-04-28 2025-03 0.96 1.01 0.05 5.21%
2025-01-31 2024-12 1.36 1.42 0.06 4.41%
Upgrade / Downgrade
Date Firm Action From To
2026-05-07 Barclays Upgrade Equal-Weight Equal-Weight
2026-05-06 JP Morgan Upgrade Neutral Neutral
2026-05-06 TD Cowen Upgrade Buy Buy
2026-05-06 Stifel Upgrade Hold Hold
2026-05-04 Baird Upgrade Outperform Outperform
2026-04-14 Goldman Sachs Upgrade Neutral Neutral
Profile
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2026-05-06 BARRETT PETER Director 28.29K Stock Award(Grant)
2026-05-06 CHAPIN SAMUEL R. Director 22.68K Stock Award(Grant)
2026-02-04 GOLDBERG JOEL S General Counsel 106.96K Sale
2026-02-03 KRAKOWIAK MAXWELL Chief Financial Officer 18.77K Stock Award(Grant)
2026-05-06 MICHAS ALEXANDROS P Director 71.54K Stock Award(Grant)
2025-08-26 MICHAS ALEXIS P Director 0.00 Sale
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 T. Rowe Price Investment Management, Inc. 22.20M 2.23B 19.90%
2026-03-30 Price (T.Rowe) Associates Inc 10.09M 1.01B 9.04%
2026-03-30 Edgepoint Investment Group Inc. 8.80M 883.39M 7.89%
2026-03-30 Janus Henderson Group PLC 8.35M 837.94M 7.48%
2026-03-30 Vanguard Capital Management LLC 7.33M 735.75M 6.57%
2026-03-30 Blackrock Inc. 7.25M 727.76M 6.50%
Fund Ownership
Report Date Organization Position Value Percentage
2026-03-30 T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App 14.15M 1.42B 12.69%
2026-03-30 JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund 5.62M 564.57M 5.04%
2025-12-30 -Price (T.Rowe) U.S. Value Equity Trust 3.92M 393.88M 3.52%
2026-03-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 3.55M 356.44M 3.18%
2026-03-30 T. Rowe Price Value Fund, Inc. 3.52M 353.05M 3.15%
2026-03-30 JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund 3.12M 313.60M 2.80%
Dividend
Dividend Date
0.07 2026-07-17
0.07 2026-04-17
0.07 2026-01-16
0.07 2025-10-17
0.07 2025-07-18
0.07 2025-04-17